Press Releases
Paradigm Clinical Research Opens Its Flagship Clinic in San Diego, Marking 15 Years of Success
Apr 3, 2024, 07:53 AM
by
Paradigm Clinical Research, a leading clinical research site business, announced the opening of its flagship clinic in San Diego, California coinciding with the celebration of the company’s 15th anniversary. This is a significant milestone in the company's growth strategy, positioning its flagship site to better serve the evolving needs of patients and the clinical research community.
“The opening of our flagship clinic solidifies Paradigm Clinical Research’s position at the forefront of the multi-location and multi-specialty clinical research site market," said Kurt Mussina, CEO of Paradigm Clinical Research. “Our operating model is ‘one site offering many locations and investigators,’ meaning all our clinics and staff function under a single, harmonized set of operating standards and principles. This positions us well to deliver industry-leading value to all stakeholders, especially patients, as evidenced by our exceptional patient Net Promoter Score® of 96. The opening of our San Diego clinic not only aligns with a decade and a half of success, but also validates our unique operating and growth strategies.”
"We are proud of the success the entire Paradigm Clinical Research team has achieved, including the opening of the company’s flagship clinic," said Aleem Choudhry, Managing Partner at Crane Street Capital. "This highlights the strength of the team’s managerial and operational expertise, providing the company with an even greater ability to meet the needs of clinical trial sponsors on so many different levels.”
Paradigm Clinical Research celebrates its 15th anniversary this year, marking a decade and a half of success supporting industry sponsored clinical trials. The company remains committed to fostering diversity and inclusion and boasts access to a distinguished team of principal investigators across several therapeutic areas and specialties.
For more information about Paradigm Clinical Research and its services, please visit paradigm-research.com.
About Paradigm Clinical Research
Paradigm Clinical Research is a long-standing clinical research site business with locations in California, Colorado, and Idaho. The company operates wholly owned sites that support Phase I-IV clinical trials and provides sponsors with access to diverse and often under-represented patient populations and investigators. Paradigm’s mission is to enrich lives by offering opportunities to advance the human condition through participation in expertly conducted clinical trials. To learn more, please visit paradigm-research.com.
About Crane Street Capital Group
Crane Street Capital Group specializes in micro growth buyouts in a few selected fragmented industries with untapped white space potential for growth. Its investments target companies that not only have outsized growth potential within their industries but also have the ability to make tremendously positive impacts within the communities in which they operate. Crane Street maintains a concentrated portfolio, deploys capital on an independent basis when outstanding opportunities are available and implements a patient approach in value creation over typically 5+-year holding periods. Currently, there are seven companies in the portfolio, four of which are in education services and three of which are in healthcare services.
“The opening of our flagship clinic solidifies Paradigm Clinical Research’s position at the forefront of the multi-location and multi-specialty clinical research site market," said Kurt Mussina, CEO of Paradigm Clinical Research. “Our operating model is ‘one site offering many locations and investigators,’ meaning all our clinics and staff function under a single, harmonized set of operating standards and principles. This positions us well to deliver industry-leading value to all stakeholders, especially patients, as evidenced by our exceptional patient Net Promoter Score® of 96. The opening of our San Diego clinic not only aligns with a decade and a half of success, but also validates our unique operating and growth strategies.”
"We are proud of the success the entire Paradigm Clinical Research team has achieved, including the opening of the company’s flagship clinic," said Aleem Choudhry, Managing Partner at Crane Street Capital. "This highlights the strength of the team’s managerial and operational expertise, providing the company with an even greater ability to meet the needs of clinical trial sponsors on so many different levels.”
Paradigm Clinical Research celebrates its 15th anniversary this year, marking a decade and a half of success supporting industry sponsored clinical trials. The company remains committed to fostering diversity and inclusion and boasts access to a distinguished team of principal investigators across several therapeutic areas and specialties.
For more information about Paradigm Clinical Research and its services, please visit paradigm-research.com.
About Paradigm Clinical Research
Paradigm Clinical Research is a long-standing clinical research site business with locations in California, Colorado, and Idaho. The company operates wholly owned sites that support Phase I-IV clinical trials and provides sponsors with access to diverse and often under-represented patient populations and investigators. Paradigm’s mission is to enrich lives by offering opportunities to advance the human condition through participation in expertly conducted clinical trials. To learn more, please visit paradigm-research.com.
About Crane Street Capital Group
Crane Street Capital Group specializes in micro growth buyouts in a few selected fragmented industries with untapped white space potential for growth. Its investments target companies that not only have outsized growth potential within their industries but also have the ability to make tremendously positive impacts within the communities in which they operate. Crane Street maintains a concentrated portfolio, deploys capital on an independent basis when outstanding opportunities are available and implements a patient approach in value creation over typically 5+-year holding periods. Currently, there are seven companies in the portfolio, four of which are in education services and three of which are in healthcare services.
